Genolution

At a glance

Genolution filed 61 disclosures in the last 12 months, including 26 insider, 8 5% holder and 2 buyback. The most recent key filing was on Oct 16: A major holder's stake rose from 27.72% to 28.65% (open-market buy).

Revenue for 2025 was ₩9.4B, up 31.8% on 2024. It made an operating loss of ₩8.6B. Debt was 38% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩5.6B and operating loss of ₩3B.

The 2025 annual report lists 76 employees with an average tenure of 3.2 years and average pay of ₩53.4M, #1290 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩88M each on average. It paid no cash dividend for 2025. (주)호일바이오메드 and related parties held 26.17% at year end.

Of 1 recent 5%+ holder report, 1 raised and 0 cut a stake; the largest stake reported was 28.65% on Oct 16.

From the 2025 annual report

Staff: 76 (39 men, 37 women), of whom 12 on fixed-term contracts. Total pay for the year: ₩4.1B. Directors and auditors: 5, paid ₩440B in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)호일바이오메드 holds 10.02%; with 10 related parties the group holds 26.17% of common shares at year end (from 26.10% at the start of the year).

Auditor: 대주회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports